FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
November 22, 2011 — Patients receiving long-term, steady-dose warfarin therapy who have had stable international normalized ratios (INRs) for at least 6 months can safely go 12 weeks between dose ...
MINNEAPOLIS, July 11, 2023 /PRNewswire/ -- ARKRAY USA, Inc., a leader in diabetes and resident care solutions to long-term care facilities, announced today the launch of Assure PT Care PT/INR ...
The Coag-Sense® PT/INR Monitoring System is based on the same mechanical principle as the World Health Organization’s gold standard manual tilt-tube technique (MTT), used to this day for calibration ...
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback